Shield Therapeutics plc (LON:STX) is the topic of conversation when Hardman & Co Analyst Dr Martin Hall joins DirectorsTalk Interviews.
Despite launching a drug into the US market, Shield has performed really badly over the past 12 months, Martin explains what happened, shares his thoughts on the considerable progress made, implications for the full year, why the share price is falling, investment capital and the investment opportunity.
Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals.
